Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2008-01-29
2008-01-29
O'Hara, Eileen B. (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S085100, C514S012200, C530S351000
Reexamination Certificate
active
07323164
ABSTRACT:
The present invention relates to the anti-cancer activity of IL-24 polypeptide molecules. IL-24 is a cytokine involved in inflammatory processes and human disease. The present invention includes Use of IL-24 for decreasing proliferation of ovarian cancer cells, treating ovarian cancer, amongst other uses disclosed. IL-24 polypeptides can be administered alone, or can be fused to cytotoxic moieties, and can be administered in conjunction with radiation or chemotherapeutic agents.
REFERENCES:
patent: 4603044 (1986-07-01), Geho et al.
patent: 5252714 (1993-10-01), Harris et al.
patent: 5382657 (1995-01-01), Karasiewicz et al.
patent: 5738846 (1998-04-01), Greenwald et al.
patent: 95/11986 (1995-05-01), None
patent: 98/28425 (1998-07-01), None
patent: 98/46638 (1998-10-01), None
patent: WO 02/45737 (2002-06-01), None
patent: 03/016499 (2003-02-01), None
patent: 03/029262 (2003-04-01), None
patent: 03/075952 (2003-09-01), None
patent: 03/082255 (2003-10-01), None
patent: 03/087308 (2003-10-01), None
Su et al. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. PNAS, Vo 98, No. 18, pp. 10332-10337, Aug. 2001.
Ramesh et al, Cancer Research, Aug. 2003. vol. 63, pp. 5105-5113.
Sieger et al Molecular therapy, Mar. 2004, vol. 9, No. 3, pp. 355-367.
Frigerio et al., 1995, (GenBank Acc. No. T24746).
Washington University School of Medicine, 1995, (GenBank Acc. No. N23949).
Washington University School of Medicine, 1995, (GenBank Acc. No. N31850).
National Cancer Institute, 1997, (GenBank Acc. No. AA281696).
National Cancer Institute, 1997, (GenBank Acc. No. AA281635).
The Institute for Genomic Research, 1995, (GenBank Acc. No. AA370517).
The Institute for Genomic Research, 1995, (GenBank Acc. No. AA370518).
The Institute for Genomic Research, 1995, (GenBank Acc. No. AA344685).
The Institute for Genomic Research. 1995, (GenBank Acc. No. AA344685).
EST985910, 1997.
Sequence from Incyte Pharmaceuticals, Inc., (No. INC1261863), 1997.
Columbia University, 1994, (Acc. No. U16261.
EST1011900, Oct. 10, 1997.
Su et al., “Melanoma differentiation associated gene-7,mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in ap53-independent manner,”Oncogene 22:1164-1180, 2003.
Saeki et al., “Inhibition of human lung cancer growth following adenovirus-mediatedmda-7gene expression in vivo,”Oncogene 21:4558-4566, 2002, issue No. 29, Jul. 2002.
Ekmekcioglu et al., “Negative Association of Melanoma Differentiation-associated Gene (mda-7) and Inducible Nitric Oxide Synthase (iNOS) in Human Melanoma: MDA-7 Regulates iNOS Expression in Melanoma Cells,”Molecular Cancer Therapeutics 2:9-17, 2003.
Gopalkrishnan, “INGN-241 Introgen,”Current Opinion in Investigational Drugs 3(12):1773-1777, 2002.
Sauane et al., “MDS-7/IL-24: novel cancer growth suppressing and apoptosis inducing cytokine,”Cytokine&Growth Factor Reviews 14:35-51, 2003.
Sarkar et al., “mda-7(IL-24): Signaling and Functional Roles,”Bio Techniques 33:S30-S39, 2002.
Garn et al., “IL-24 is Expressed by Rat and Human Macrophages,”Immunobiol. 205:321-334, 2002.
Sarkar et al., “mda-7(IL-24) mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK,”PNAS 99(15):10054-10059, 2002.
Sauane et al., “Mda-7/IL-24 Induces Apoptosis of Diverse Cancer Cell Lines Through JAK/STAT-Independent Pathways,”J. Cell. Physiol. 196:334-345, 2003.
Caudell et al., “The Protein Product of the Tumor Suppressor Gene, Melanoma Differentiation-Associated Gene 7. Exhibits Immunostimulatory Activity and Is Designated IL-24,”J. Immunol.6041-6046, 2002.
Parrish-Novak, et al., “Interleukins 19, 20, and 24 Signal through Two Distinct Receptor Complexes,”J. Biol. Chem. 277(49):47517-47523, 2002.
Kotenko, “The family of IL-10-related cytokines and their receptors: related, but to what extent?.”Cytokine&Growth Factor Reviews 13:223-240, 2002.
Lebedeva et al., “Bcl-2 and Bcl-xL differentially protect human prostate cancer cells from induction of apoptosis by melanoma differentiation associated gene-7,mda-7/IL-24,”Oncogene 22:8758-8773, 2003.
Vandenbroeck et al., “The Conserved Helix C Region in the Superfamily of Interferon-γ/Interleukin-10-related Cytokines Corresponds to a High-affinity Binding Site for the HSP70 Chaperone DnaK,”J. Biol. Chem. 277(29):25668-25676, 2002.
Collins, “Generation and intial analysis of more than 15, 000 full-length human and mouse cDNA sequences,”PNAS 99(26):16899-16903, 2002.
Kamps et al., “Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells,”Proc. Natl. Acad. Sci. USA 94:11681-11685, 1997.
Chang et al., “Molecular Advances in Pretargeting Radioimmunotherapy with Bispecific Antibodies,”Mol. Can. Ther. 1:553-563, 2002.
Jiang et al., “The melanoma differentiation associated gene mda-7 suppresses cancer cell growth,”Proc. Natl. Acad. Sci. USA 93:9160-9165, 1996.
O'Reilly et al., “Angiostatis: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma,”Cell 79:315-328, 1994.
Rusciano et al., “Murine Models of Liver Metastasis,”Invasion Metastasis 95(14):349-361, 1994.
Molpus et al., “Characterization of a Xenograft Model of Human Ovarian Carcinoma Which Prodces Intraperitoneal Carcinomatosis and Metastases in Mice,”Int. J. Cancer 67:588-595, 1996.
Moreno-Merlo et al., “Association between tissue hypoxia and elevated non-protein sulphydryl concentrations in human cervical carcinoma xenografts,”British Journal of Cancer 81(6):989-993, 1999.
Vukovic et al.,“Multiparameter Fluorescence Mapping of Nonprotein Sulfhydryl Status in Relation to Blood Vessels and Hypoxia in Cervical Carcinoma Xenografts,”Int. J. Radiation Oncology Biol. Phys. 52(3):837-843, 2002.
Delgado et al.. “The Uses and Properties of PEG-Linked Proteins,”Critical Reviews in Therapeutic Drug Carrier Systems 9(3,4):249-304, 1992.
Duncan et al., “Polymer Conjugates, Pharmacokinetic Considerations for Design and Development,”Clin. Pharmacokinet 27(4):290-306, 1994.
Francis et al., “PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques,”International J. of Hematology 68:1-18, 1998.
Monkarsh et al., “Positional Isomers of Monopegylated Interferon α-2a: Isolation, Characterization, and Biological Activity,”Analytical Biochemistry 247:434-440, 1997.
Ranade and Hollinger, Drug Delivery Systems (CRC Press, 1996).
Bremer et al., “Protein Delivery with Infusion Pumps,” inProtein Delivery:Physical Systems, Sanders and Hendren (eds.) pp. 239-254 (Plenum Press, 1997).
Yewey et al., “Delivery of Proteins from a Controlled Release Injectable Implant,”Protein Delivery:Physical Systems, Sanders and Hendren (eds.), pp. 93-117 (Plenum Press, 1997).
Bakker-Woudenberg et al., “Liposomes as Carriers of Antimicrobial Agents or Immunomodulatory Agents in the Treatment of Infections,”Eur. J. Clin. Microbiol. Infect. Dis. 1:61-67, 1993.
Ranade, “Site-Specific Drug Delivery Using Liposomes as Carriers,” inDrug Delivery Systems, Ranade and Hollinger (eds.), pp. 3-24 (CRC Press, 1995).
Ostro et al., “Use of liposomes as injectable-drug delivery systems.”American J. of Hospital Pharmacy 46:15761587, 1989.
Scherphof et al., “Uptake and Intracellular Processing of Targeted and Nontargeted Liposomes by Rat Kupffer Cells In Vivo and In Vitro,”Ann. N.Y. Acad. Sci. 446:368-385,1985.
Claassen et al., “The Effect of Elimination of Macrophages on the Tissue Distribution of Liposomes Containing [3H]Metho
Chandrasekher Yasmin A.
McKernan Patricia A.
Hamud Fozia
O'Hara Eileen B.
Schutzer Aaron A.
Walker Shelby J.
ZymoGenetics Inc.
LandOfFree
Use of interleukin-24 to treat ovarian cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of interleukin-24 to treat ovarian cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of interleukin-24 to treat ovarian cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2778023